Caribou Biosciences, Inc.

Clinical trials sponsored by Caribou Biosciences, Inc., explained in plain language.

Caribou Biosciences, Inc. CRBU NASDAQ

A clinical-stage biopharmaceutical company developing CRISPR-based cell therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 2

Gene-Edited immune cells take on Hard-to-Treat blood cancer

Disease control Recruiting now

This early-stage study tests a new treatment called CB-011 for people with multiple myeloma that has returned or stopped responding to other therapies. CB-011 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The study aims to find the saf…

Phase 1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

Caribou Biosciences, Inc.

Gene-Edited immune cells take on Hard-to-Treat blood cancer